2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1889

Safety and Efficacy of Denosumab Among Subjects with Mild-to-Moderate Chronic Kidney Disease (CKD) in the “Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months” Extension Study
Abstract Number: 1890

Persistent Fracture Reduction with Abaloparatide-SC (TYMLOS™) Followed By 24 Months of Alendronate
Abstract Number: 1891

Low Alkaline Phosphatase Levels: Could It be Hypophosphatasia?
Abstract Number: 1892

A20 Haploinsufficiency: Clinical Phenotypes and Disease Course of Patients with This Newly Recognized Autoinflammatory Disease
Abstract Number: 1893

Pharmacokinetics (PK), Pharmacodynamics (PD), and Proposed Dosing of Oral Janus Kinase (JAK)1 and JAK2 Inhibitor Baricitinib in Patients with IFN-Mediated Autoinflammatory Diseases (AIDs)
Abstract Number: 1894

Genetic Phenotypes Impacting Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant FMF, TRAPS and Hids/Mkd: Results from Cluster Study
Abstract Number: 1895

Serum Interleukin 18 As a Biomarker for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome and Use of Recombinant Human IL-18 BP in a Patient with Refractory Disease
Abstract Number: 1896

IL-18 As a Diagnostic Biomarker, Differentiating Systemic JIA from Acute Leukaemia, Severe Bacterial Infections and Other Auto-Immune Disorders
Abstract Number: 1897

the Ferritin to ESR Ratio: A Simple Measure to Distinguish Macrophage Activation Syndrome from Systemic Arthritis Flare
Abstract Number: 1898

Overweight/Obesity Affect Histological Features of Synovial Membrane of Rheumatoid Arthritis Patients from Disease Onset to Stable Remission Achievement
Abstract Number: 1899

Osteopontin and Leptin Are Associated with Erosive Disease in an Inception Cohort of Rheumatoid Arthritis Treated-to-Target with Combination Conventional DMARD Therapy
Abstract Number: 1900

Effect of Age and Body Mass Index (BMI) on Multi-Biomarker Disease Activity (MBDA) Score in Patients with Rheumatoid Arthritis
Abstract Number: 1901

Unfavorable Body Composition Already at the Onset of Clinical Arthritis
Abstract Number: 1902

A Pattern of Higher Serum Levels of IL-10 and MMP-3, Along with Lower IL-6R, Identify RA Patients with Interstitial Lung Disease
Abstract Number: 1903

Can Achieving Sustained DAS Remission Prevent Arterial Stiffness Progression in Early Rheumatoid Arthritis – a Post-Hoc Analysis of a Randomized Controlled Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].